Tag Archives: gild

Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar?

The IBD 50 is a ranking of leading stocks based on key fundamental and technical measures including earnings and sales growth, profit margins, return on equity and relative price performance. Here’s a closer look at four drug stocks that made the new list Friday: Regeneron Pharmaceuticals (REGN), Valeant Pharmaceuticals (VRX), Actavis (ACT) and Gilead Sciences (GILD). Regeneron has a highest possible IBD Composite Rating of 99. On Friday, the FDA

Meet 8 Hot Med Stocks Among IBD’s Big Cap Leaders

IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all

Gilead-GlobeImmune Hepatitis B Drug Fails Trial

Biotech GlobeImmune (GBIM) said Wednesday that a hepatitis B drug it’s developing with Gilead Sciences (GILD) failed a midstage trial. GlobeImmune stock lost half its value, but Gilead stock rose. GlobeImmune said that GS-4774, a therapeutic vaccine that it licensed to Gilead, didn’t meet the trial’s primary endpoint of reducing the hepatitis B surface antigen (HBsAG) after 24 weeks of treatment, though GlobeImmune CEO Timothy Rodell said the